Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV vaccine - Institute of Human Virology/Profectus Biosciences

Drug Profile

HIV vaccine - Institute of Human Virology/Profectus Biosciences

Alternative Names: AIM Therapy - Profectus BioScience; anti-HIV antibodies - Profectus BioScience; FLSC vaccine; Full-length single chain vaccine; IHV 001; IHV 01

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Profectus Biosciences
  • Developer Institute of Human Virology; Profectus Biosciences
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 08 Dec 2020 U.S. Army Medical Research and Development Command plans a phase I trial for HIV infections (Prevention, Combination therapy, In adults, In the elderly) in March 2021 in Thailand (IM) (NCT04658667)
  • 28 Nov 2018 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (Parenteral)
  • 01 Jul 2018 Institute of Human Virology, in collaboration with Profectus Biosciences completes a phase I trial in HIV infections (In volunteers, Prevention) in USA (IM) (NCT02756208)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top